Pharmaceutical / Drug Definition :
Inhibits fast sodium channels of myocardial cell membrane. Also slows conduction, shortens action potential, stops paroxysmal reentrant supraventricular tachycardia, and decreases conduction in accessory pathways in Wolff-Parkinson-White syndrome.
In the United States, Flecainide Acetate is regulated by the U.S. Food and Drug Administration (FDA). FDA has specific requirements regarding the registration and listing of Flecainide Acetate.
FDA Label Requirements and Exceptions
FDA Import Information
Flecainide Acetate (Flecainide Acetate Entry Refusal)
General U.S. Food and Drug Administration Guidelines for:
- Manufacturers Flecainide Acetate (Flecainide Acetate Suppliers)
- Processors Flecainide Acetate
- Repackers Flecainide Acetate
- Relabelers Flecainide Acetate
- Exporters Flecainide Acetate
- Importers Flecainide Acetate
For more information about Flecainide Acetate, simply click below:
U.S. FDA Regulations:
U.S. FDA Regulation: 21 C.F.R. Part 207
Registrar Corp assists businesses with U.S. FDA compliance. Certificates of Registration issued by Registrar Corp provide confirmation to industry that you are fulfilling U.S. FDA registration requirements. U.S. FDA does not issue or recognize Certificates of Registration. Registrar Corp is not affiliated with the U.S. Food and Drug Administration.